MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To guage multiple intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major demo targets were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers… Read More